ONGOZIG Trademark

Trademark Overview


On Friday, April 17, 2020, a trademark application was filed for ONGOZIG with the United States Patent and Trademark Office. The USPTO has given the ONGOZIG trademark a serial number of 88877227. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, May 20, 2024. This trademark is owned by Celgene Corporation. The ONGOZIG trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
ongozig

General Information


Serial Number88877227
Word MarkONGOZIG
Filing DateFriday, April 17, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, May 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 16, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 27, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Tuesday, April 21, 2020NEW APPLICATION ENTERED
Monday, April 27, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, July 8, 2020ASSIGNED TO EXAMINER
Monday, January 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, July 14, 2020NON-FINAL ACTION WRITTEN
Tuesday, July 14, 2020NON-FINAL ACTION E-MAILED
Tuesday, July 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 27, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 16, 2021PUBLISHED FOR OPPOSITION
Tuesday, April 13, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, October 13, 2021SOU TEAS EXTENSION RECEIVED
Thursday, January 14, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, February 16, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, March 29, 2021ASSIGNED TO EXAMINER
Wednesday, October 13, 2021SOU EXTENSION 1 FILED
Wednesday, October 13, 2021SOU EXTENSION 1 GRANTED
Friday, October 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 6, 2022SOU TEAS EXTENSION RECEIVED
Thursday, October 6, 2022SOU EXTENSION 3 FILED
Friday, April 8, 2022SOU TEAS EXTENSION RECEIVED
Friday, April 8, 2022SOU EXTENSION 2 FILED
Friday, April 8, 2022SOU EXTENSION 2 GRANTED
Thursday, October 6, 2022SOU EXTENSION 3 GRANTED
Saturday, October 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 29, 2023SOU TEAS EXTENSION RECEIVED
Friday, March 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 3, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, October 3, 2023SOU EXTENSION 5 FILED
Friday, October 13, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, October 13, 2023SOU EXTENSION 5 GRANTED
Wednesday, March 29, 2023SOU EXTENSION 4 FILED
Wednesday, March 29, 2023SOU EXTENSION 4 GRANTED
Saturday, October 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 20, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, May 20, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED